leadf
logo-loader
viewTodos Medical Ltd.

Todos Medical reveals positive clinical proof of concept data from its rapid coronavirus test

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the group has “positive clinical proof of concept data” from its lab-based rapid SARS-CoV-2 3CL protease diagnostic test in collaboration with its joint venture partner NLC Pharma.

Commissiong says now, the group is gathering additional clinical data to submit an emergency use authorization to the FDA for its lab-based test to be distributed through the company’s existing lab distribution channels.

Quick facts: Todos Medical Ltd.

Price: 0.0575 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $11.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical growing the business with COVID-19 testing sales heading into...

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong updated shareholders tell Proactive it expects revenues generated from sales of its COVID-19 testing solutions to be a near-term driver of business. Commissiong says the group eported revenue of $867,000 in October 2020, a 147%...

1 week, 6 days ago

2 min read